IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market

September 23, 2020

IRLAB Therapeutics AB (“IRLAB” or the “Company”) today announced that Nasdaq Stockholm’s listing committee on September 22, 2020 has approved IRLAB’s application for admission to trading of the Company’s shares of series A on Nasdaq Stockholm Main Market. The approval is subject to fulfilment of customary conditions, including approval and registration of a prospectus by the Swedish Financial Supervisory Authority. The Company’s shares of series A are currently traded on Nasdaq First North Premier Growth Market under the ticker IRLAB A.

[mfn_before_post]

IRLAB Therapeutics AB (”IRLAB” or the “Company”) today announced that Nasdaq Stockholm's listing committee on September 22, 2020 has approved IRLAB’s application for admission to trading of the Company’s shares of series A on Nasdaq Stockholm Main Market. The approval is subject to fulfilment of customary conditions, including approval and registration of a prospectus by the Swedish Financial Supervisory Authority. The Company’s shares of series A are currently traded on Nasdaq First North Premier Growth Market under the ticker IRLAB A.

The first day of trading on Nasdaq Stockholm Main Market is expected to be Wednesday, September 30, 2020, and the last day of trading on Nasdaq First North Premier Growth Market is expected to be Tuesday, September 29, 2020.

The shares will continue to be traded under the same ticker (IRLAB A) and ISIN code (SE0012675361). No new shares will be issued in connection with the list change and the shareholders in IRLAB do not need to take any measures in connection with the list change.

"The listing of IRLAB on Nasdaq Stockholm Main Market entails increased visibility and transparency and is a quality seal on our organization and operations. In our opinion, this is a significant step towards becoming an internationally reputable drug development company," says Nicholas Waters, CEO.

Prospectus

IRLAB has prepared a prospectus in connection with the admission to trading of the Company’s shares of series A on Nasdaq Stockholm. The prospectus is expected to be approved and registered by the Swedish Financial Supervisory Authority and published on IRLAB’s website, www.irlab.se, on or around Friday, September 25, 2020.

Advisor

MAQS Advokatbyrå is the Company’s legal advisor in connection with the listing on Nasdaq Stockholm.

For more information

Nicholas Waters, CEO                
Phone: +46 730 75 77 01                
E-mail: nicholas.waters@irlab.se

Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se

This is such information that IRLAB Therapeutics AB is obligated to make public in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at September 23, 2020 at 15:15 CET.

About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North Premier Growth Market is FNCA Sweden AB, info@fnca.se, +46 (0)8528 00 399. More information on www.irlab.se.  

[mfn_after_post]

Documents & Links